STORY INLINE POST
Q: How does Stendhal’s recent partnership with Adalvo align with the company's overall business objectives?
A: Rather than being bound to a predetermined portfolio, Stendhal Pharma seeks innovative pharmaceutical solutions to meet unmet healthcare needs in the regions we serve. Our collaboration with Adalvo seamlessly aligns with this guiding philosophy and represents a valuable addition to our product portfolio. This strategic partnership centers around an antibiotic developed for the treatment of acute bacterial skin and skin structure infections (ABSSI). The demand for antibiotics designed to treat conditions like ABSSI is high in Mexico. This product will be available in Mexico and Colombia, addressing the healthcare needs in multiple Latin American regions. This innovative treatment has the potential to improve the quality of life for patients facing these challenges.
Our partnership with Adalvo reflects our commitment to stay at the forefront of healthcare advances and meet emerging healthcare needs while remaining consistent with our core mission.
Q: What challenges does the pharmaceutical industry face in Mexico?
A:Each administration implements its public policy. Collaboration between companies, associations and authorities is necessary to avoid challenges that deter the timely emergence of innovative medicines.
We actively participate with CANIFARMA & AMIIF to stay informed about the evolving trends that shape Mexico's pharmaceutical landscape. There are abundant opportunities and there is untapped potential to harness them through forums and discussions.
Q: How has demand for Stendhal Pharma’s solutions changed following the COVID-19 pandemic?
A: Demand underwent a significant transformation in the wake of the COVID-19 pandemic, which catalyzed change, particularly in our approach to engaging with healthcare professionals. The rapid shift to digital platforms streamlined our interactions with physicians. During the pandemic, we recognized the importance of ensuring continuous communication channels with healthcare providers, leading us to explore additional parts of our portfolio that were previously overlooked. In the post-pandemic era, we find ourselves stronger than ever.
We proactively identified potential risks and bolstered our planning and logistics systems to prevent shortages, which brought substantial benefits. Demand for antibiotics grew during this period, leading us to enhance our capabilities to locate and respond to these needs swiftly.
Q: How does Stendhal Pharma incorporate the rapid advancements in technology into its business practices?
A: We actively acquire software and harness the power of AI to assess knowledge and skills. Robots for information technology and data processing are taking a pivotal role in managing the vast data influx of today's digital landscape. These tools provide opportunities for growth and innovation. The challenges include effectively transforming this wealth of data into actionable insights, which requires substantial investments in robust data processing capabilities.
In essence, Stendhal Pharma's strategy is to leverage these advances to enhance our knowledge-assessment capabilities. We embrace these changes with enthusiasm and optimism, confident that they will propel us toward even greater achievements in the future.
Q: How does Stendhal Pharma prioritize sustainability, responsible practices and employee well-being in its business approach?
A: At Stendhal Pharma, sustainability is central to our business approach. We are proudly an officially responsible company, deeply committed to environmental stewardship and to enhancing the well-being of our employees and the environment. For example, we engage in meticulous garbage separation procedures.
We set ambitious goals for the coming years. For example, we outlined a visionary plan to transition a significant portion of our vehicle fleet to hybrid models by 2024. Sustainability is not just about the environment; it is also about our core values, including ethical business practices. Stendhal Pharma takes pride in its robust business ethics policies, which have earned certification from organizations like CEMEFI. These policies guide our conduct and reinforce our commitment to responsible, ethical and sustainable business practices.
Q: What are the company’s priorities for 1Q24?
Our top priorities for the first quarter of 2024 are centered around product launches, specifically in the realm of orphan drugs. These launches pose a significant challenge due to the need for substantial predefining of investments and strategic planning. Stendhal Pharma became a pivotal player in Central America’s orphan drug market without relying on external alliances. In addition to expanding our portfolio, we are heavily investing in our medical team and salesforce to ensure we maintain a strong presence in the market. We believe there are abundant opportunities in the pharmaceutical sector and we are committed to harnessing them to benefit patients and the industry as a whole.